Toft Group Completes Executive Search for NanoString Technologies, Inc. (Nasdaq: NSTG) in Seattle, WA


Executive search firm Toft Group has placed Mr. Brett Jensen as North American Sales Director, Diagnostics at NanoString Technologies, Inc. in Seattle, WA. Mr. Brett Jensen is a healthcare sales and marketing leader with more than 25 years of experience in molecular diagnostics and pharmaceuticals. He previously served as Vice President of Sales at Transplant Genomics Incorporated in Brookline, MA. Earlier in his career, Mr. Jensen held positions with Myriad Genetics and GlaxoSmithKline.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.